Health & Medicine | Nov 18, 2026 | 12 min read | By Bryan White

Marrow Therapeutics Raises $173M for Bone Marrow-Targeted siRNA to Rival CRISPR in Sickle Cell Disease

Health & Medicine * Natural Science * Research Dispatch

Marrow Therapeutics, a Watertown, Massachusetts-based biotechnology company, emerged in November 2026 with 173 million dollars in combined Series A and Series B financing to advance an in vivo , bone marrow-targeted small interfering RNA (siRNA) therapeutic designed to compete directly with one-time ex vivo CRISPR gene-editing therapies for sickle cell disease and beta-thalassemia. Comprising a 53 million dollar Series A co-founded and co-led by Scion Life Sciences and venBio alongside a 120 million dollar Series B led by OrbiMed, the financing funds Investigational New Drug (IND)-enabling preclinical development of MAR-101, an antibody-siRNA bioconjugate engineered to silence the master fetal-hemoglobin repressor gene BCL11A inside bone marrow erythroid progenitors without stem cell harvesting or myeloablative chemotherapy.

Approved one-time genetic medicines such as exagamglogene autotemcel (Casgevy) proved clinically that disrupting BCL11A expression in hematopoietic stem and progenitor cells restores protective fetal hemoglobin (HbF) and eliminates vaso-occlusive crises in most treated patients. Yet the grueling clinical infrastructure required for ex vivo editing -- multi-month cell mobilization and apheresis, bespoke viral or electroporation manufacturing, and busulfan myeloablative conditioning that carries infertility and secondary-malignancy risks -- has severely constrained global patient uptake. Marrow's Transferrin Antibody Bioconjugate (TAB) strategy attempts to preserve the exact genetic target validated by CRISPR while shifting delivery from a one-time transplant procedure to a repeatable, systemically administered biologic.

Molecular Pathophysiology of Sickle Cell Disease and Fetal Hemoglobin Rescue

Sickle cell disease arises from a single point mutation in the HBB gene encoding the beta-globin subunit of adult hemoglobin (HbA, composed of two alpha-globin and two beta-globin chains: alpha 2 beta 2). Substituting glutamic acid with valine at position 6 of the beta-globin chain generates sickle hemoglobin (HbS). Under deoxygenated conditions inside capillary beds, hydrophobic interactions between exposed valine residues drive HbS tetramers to polymerize into rigid, elongated intracellular fibers that distort biconcave erythrocytes into stiff, sickle-shaped cells.

Deformed erythrocytes exhibit markedly shortened circulatory half-lives, causing chronic hemolytic anemia, while adhering abnormally to vascular endothelium and obstructing microvascular blood flow. Downstream ischemia-reperfusion injury, nitric oxide scavenging by cell-free plasma hemoglobin, and sterile vascular inflammation manifest clinically as recurrent vaso-occlusive pain crises, acute chest syndrome, progressive stroke risk, and cumulative end-organ damage across the kidneys, spleen,

and cardiopulmonary vasculature.

Human physiology already encodes an endogenous genetic bypass for mutant beta-globin. During fetal development, erythroid cells express gamma-globin chains encoded by the duplicated HBG1 and HBG2 loci, pairing with alpha-globin to assemble fetal hemoglobin (HbF, alpha 2 gamma 2). Because gamma-globin lacks the surface geometry needed to co-polymerize efficiently with deoxygenated HbS tetramers, even modest fractions of pancellular HbF -- typically 20 to 30 percent or higher across circulating red blood cells -- potently inhibit intracellular sickling by diluting HbS concentration and sterically interrupting polymer elongation. In addition, the delay time before rapid HbS fiber nucleation scales steeply as an inverse high-power function of intracellular deoxy-HbS concentration; consequently, modest increases in HbF per cell disproportionately extend capillary transit survival beyond the time required for red blood cells to return to the lungs and re-oxygenate. Following birth, however, a tightly coordinated developmental switch silences gamma-globin transcription and activates adult beta-globin expression, unmasking sickle cell pathology within the first year of life.

The same fetal-hemoglobin reactivation logic applies directly to beta-thalassemia, the second indication targeted by Marrow Therapeutics. Whereas sickle cell disease stems from a qualitative structural variant in beta-globin, beta-thalassemia arises from quantitative reductions or complete absence of beta-globin chain synthesis. Unpaired alpha-globin chains precipitate as insoluble hemichromes inside bone marrow erythroid precursors, triggering oxidative membrane damage, premature apoptosis , and ineffective erythropoiesis. Restoring gamma-globin synthesis via BCL11A silencing supplies functional binding partners to sequester excess alpha-globin into stable HbF tetramers, rescuing erythroid maturation and alleviating transfusion dependence.

BCL11A as the Master Transcriptional Gatekeeper of Hemoglobin Switching

For decades, pharmacological attempts to re-induce HbF relied on small molecules such as hydroxyurea, which modestly elevates gamma-globin through stress erythropoiesis and ribonucleotide-reductase inhibition but leaves many patients with incomplete protection or dose-limiting cytopenias. The modern era of targeted HbF reactivation began with genome -wide association studies and mechanistic work led by Vijay G. Sankaran, Stuart H. Orkin, and colleagues in Science (2008), which established the zinc -finger transcription factor BCL11A as the primary developmental repressor of human fetal hemoglobin.

During adult erythropoiesis, BCL11A binds directly to TGACCA motifs within the proximal promoters of HBG1 and HBG2 , recruiting chromatin -remodeling and corepressor complexes -- including NuRD -- to compact chromatin and extinguish gamma-globin transcription. Crucially, the beta-globin locus control region (LCR) dynamically competes between gamma-globin and beta-globin promoters; reducing BCL11A abundance releases that repression, allowing the LCR to loop back onto HBG1 / HBG2 promoters and drive robust HbF synthesis while simultaneously lowering mutant beta S -globin output.

In 2021, Haydar Frangoul and collaborators reported landmark clinical

proof-of-concept in the New England Journal of Medicine showing that CRISPR-Cas9 editing of the erythroid-specific +58 kilobase intronic enhancer of BCL11A in autologous CD34 + hematopoietic stem cells produced durable, high-level pancellular HbF induction and transfusion independence in patients with sickle cell disease and transfusion-dependent beta-thalassemia. That clinical validation de-risked BCL11A as a therapeutic node -- while leaving open the delivery question of whether BCL11A must be permanently edited ex vivo or can instead be silenced transiently in vivo .

| Therapeutic Dimension | | Ex Vivo CRISPR / Lentiviral Gene Therapy | | In Vivo Antibody-siRNA Bioconjugate (MAR-101) |

| Molecular Target | | BCL11A erythroid enhancer DNA (permanent edit) | | BCL11A mRNA transcript (reversible RISC cleavage) |

| Cell Harvesting & Conditioning | | Requires apheresis & myeloablative busulfan conditioning | | None; direct systemic injection to bone marrow progenitors |

| Delivery Architecture | | Autologous CD34 + HSPCs modified outside the body | | Transferrin Antibody Bioconjugate (TfR1 / CD71-targeted) |

| Dosing & Reversibility | | One-time irreversible genomic modification | | Chronically dosed, titratable, & reversible RNAi silencing |

| Manufacturing & Access | | Patient-specific autologous cell manufacturing bottleneck | | Off-the-shelf scalable biologic-oligonucleotide conjugate |

Transferrin Receptor 1 Bioconjugates: Cracking Extrahepatic Bone Marrow Delivery

The central pharmacological obstacle for RNA interference (RNAi) therapeutics has never been target potency inside the cytoplasm -- it has been tissue-specific delivery. Unmodified double-stranded siRNAs are rapidly cleared by renal filtration, degraded by serum nucleases, and electrostatically repelled by negatively charged cell membranes. While N-acetylgalactosamine (GalNAc) conjugation solved hepatocyte delivery by exploiting the asialoglycoprotein receptor, and lipid nanoparticles (LNPs) naturally accumulate in the liver, achieving selective, high-efficiency siRNA uptake inside bone marrow erythroid progenitors remained notoriously difficult.

Marrow Therapeutics addresses this barrier through its Transferrin Antibody Bioconjugate (TAB) platform, which hijacks Transferrin Receptor 1 (TfR1, also designated CD71) as an active transport portal into developing red blood cell precursors. Because committed erythroid progenitors require massive quantities of iron to synthesize heme for hemoglobin assembly, they express TfR1 at extraordinarily high surface densities compared with most quiescent somatic tissues -- and constitutively internalize TfR1 via clathrin-mediated endocytosis.

By covalently linking a chemically stabilized BCL11A -targeting siRNA payload to an anti-TfR1 monoclonal antibody or engineered antibody fragment, MAR-101 acts as a molecular Trojan horse. Upon intravenous or subcutaneous administration, the antibody moiety binds a non-competing epitope on TfR1 -- avoiding interference with endogenous iron-loaded holo-transferrin binding -- on circulating or marrow-resident erythroid precursors, triggering receptor-mediated internalization into early endosomes. Unlike simple iron-loaded transferrin -- which releases iron at acidic

endosomal pH and recycles back to the surface -- engineered antibody-oligonucleotide conjugates are tuned to promote endosomal escape of the siRNA duplex into the cytosol, where the antisense guide strand loads into Argonaute-2 (AGO2) within the RNA-induced silencing complex (RISC).

From a bioconjugate chemistry perspective, achieving reliable activity requires balancing three competing design constraints: serum stability of the linker, drug-to-antibody ratio (DAR), and endosomal escape efficiency. Linkers must remain stable in peripheral circulation so that siRNA payloads do not dissociate prematurely into plasma and undergo rapid renal clearance, yet release or orient the duplex cleanly once trafficked inside maturing erythroblasts. Meanwhile, because endosomal entrapment remains the primary quantitative bottleneck for all macromolecular oligonucleotide therapeutics -- with only a small fraction of internalized siRNA typically crossing the endosomal lipid bilayer -- high receptor copy number on erythroid precursors and rapid TfR1 recycling kinetics are critical to accumulating catalytically sufficient AGO2-RISC complexes inside the cytoplasm.

Intracellular RNAi Kinetics Versus Permanent Enhancer Disruption

Once loaded into AGO2-RISC, the MAR-101 antisense strand hybridizes with complementary BCL11A messenger RNA transcripts, catalyzing sequence-specific endonucleolytic cleavage and halting translation of new BCL11A repressor protein. Because RISC acts catalytically -- destroying multiple mRNA copies per loaded complex -- and chemically modified siRNA backbones (incorporating 2'-fluoro, 2'-O-methyl, and phosphorothioate linkages) resist intracellular exonucleases for weeks, a single dose can sustain target knockdown across multiple waves of erythroid maturation.

Nevertheless, kinetic differences between permanent enhancer editing and reversible mRNA knockdown introduce distinct biological tradeoffs. In ex vivo CRISPR therapy, editing the +58 kb BCL11A enhancer in long-term hematopoietic stem cells propagates permanently into every daughter erythroid lineage for life, consistently driving HbF fractions above 40 percent once engraftment stabilizes. By contrast, an in vivo siRNA bioconjugate must maintain sufficient intracellular RISC occupancy throughout the proliferative burst from proerythroblasts through polychromatic erythroblasts -- before developing red cells enucleate and lose transcriptional machinery -- while avoiding saturation of TfR1 in non-erythroid tissues such as skeletal muscle or brain capillary endothelium. Furthermore, because maturing erythroid precursors undergo multiple rapid cell divisions inside the bone marrow, each mitotic cycle dilutes intracellular AGO2-RISC concentration by half, requiring either high initial cytoplasmic loading or sustained multi-week dosing intervals to prevent heterocellular "mosaic" HbF expression where some red cells remain unprotected.

Equally important is lineage selectivity inside the hematopoietic hierarchy. BCL11A plays an essential role in B-lymphocyte development and hematopoietic stem cell maintenance; in fact, complete constitutive loss of BCL11A across all blood lineages impairs B-cell lymphopoiesis. Ex vivo CRISPR therapies sidestep this toxicity by targeting the strictly erythroid-restricted +58 kb enhancer rather than coding exons. For MAR-101, avoiding B-cell or stem-cell suppression depends on the preferential expression gradient of TfR1: rapidly dividing erythroid progenitors

express orders of magnitude more CD71 than resting hematopoietic stem cells or mature lymphocytes, creating a receptor-density window for selective BCL11A silencing.

Bypassing Myeloablative Conditioning and Apheresis Bottlenecks

Even if chronic siRNA dosing requires periodic clinic visits rather than a single curative infusion, eliminating myeloablative conditioning represents a profound clinical differentiator. Before receiving Casgevy or lentiviral gene therapy, patients with sickle cell disease must undergo multi-day high-dose intravenous busulfan chemotherapy to ablate existing bone marrow stem cells and create niche space for edited cells. Busulfan conditioning causes prolonged neutropenia and thrombocytopenia, mucositis, hair loss, hospitalization-grade infection risk, and high rates of premature ovarian failure or azoospermia -- often requiring fertility preservation before treatment.

In addition, mobilizing peripheral blood stem cells in sickle cell patients is uniquely hazardous: granulocyte colony-stimulating factor (G-CSF), standard in oncology transplants, can trigger fatal vaso-occlusive crises in sickle cell disease, forcing clinicians to rely on plerixafor mobilization and repeated apheresis cycles alongside pre-collection red-cell exchange transfusions. By delivering BCL11A silencing directly in vivo to native marrow progenitors, MAR-101 bypasses mobilization, apheresis, ex vivo cell processing, and busulfan toxicity entirely -- making disease-modifying genetic therapy plausible for pediatric patients, older adults with organ comorbidities, and healthcare settings lacking bone marrow transplant units.

Translational Toxicology, Iron Homeostasis, and Clinical Trial Benchmarks

Advancing MAR-101 from IND-enabling preclinical models into human clinical trials requires careful evaluation of three translational safety axes. First, because TfR1 mediates physiological iron uptake into red blood cell precursors, non-human primate and rodent toxicology studies must verify that chronic antibody-bioconjugate binding does not induce TfR1 downregulation, functional iron-restricted erythropoiesis, or microcytic anemia -- even when using an antibody clone engineered against a non-transferrin-competing epitope. Second, immune-complex safety and Fc-effector silencing (such as LALA-PG or equivalent Fc-null mutations) are standard prerequisites for anti-TfR1 antibodies so that circulating reticulocytes and marrow erythroblasts are never flagged for complement-dependent cytotoxicity or antibody-dependent cellular phagocytosis.

Third, clinical proof-of-concept will be judged against rigorous hematologic benchmarks established by approved genetic therapies and hydroxyurea standards of care. Investigators will track not only mean total HbF percentage -- typically aiming for 20 to 30 percent or greater -- but also the fraction of F-cells (erythrocytes carrying protective HbF levels) by flow cytometry, reductions in hemolytic biomarkers (lactate dehydrogenase, indirect bilirubin, and reticulocyte count), and durable suppression of vaso-occlusive crises. Demonstrating consistent pancellular HbF induction on a convenient outpatient dosing schedule would position

TfR1-targeted RNA interference as a transformative bridge between oral small molecules and myeloablative gene-editing transplants.

Pharmacoeconomic Scaling and the Competitive Landscape

With list prices for approved ex vivo sickle cell gene therapies exceeding 2 million dollars per patient -- and hospital transplant infrastructure capping annual treatment capacity at specialized academic centers -- only a tiny fraction of the estimated 100,000 U.S. patients and millions of individuals globally living with sickle cell disease or beta-thalassemia can realistically access current genetic cures. An off-the-shelf antibody-siRNA conjugate manufactured through standardized biologic and solid-phase oligonucleotide synthesis scales completely differently from patient-specific cell therapy.

Still, Marrow Therapeutics enters a crowded race toward accessible in vivo sickle cell medicines. Rival approaches span oral small-molecule fetal-hemoglobin inducers (such as molecular glues degrading transcription factors like WIZ or ZBTB7A), oral HbS polymerization inhibitors, and in vivo lipid nanoparticle base-editing platforms aiming for one-shot marrow editing without conditioning. Demonstrating in upcoming IND-enabling toxicology and first-in-human trials that MAR-101 achieves durable, pancellular HbF elevation above the ~20 to 30 percent anti-sickling threshold -- without anemia-exacerbating iron disruption from TfR1 engagement or off-target B-cell depletion -- will determine whether targeted RNA interference can bridge the gap between chronic small molecules and one-time genomic cures.

References & Primary Sources

* [1] Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008). Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A. Science, 322(5909), 1839-1842. -- https://doi.org/10.1126/science.1165409

* [2] Frangoul, H., Altshuler, D., Cappellini, M. D., et al. (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. New England Journal of Medicine, 384(3), 252-260. -- https://doi.org/10.1056/NEJMoa2031054

* [3] Marrow Therapeutics (2026). Marrow Therapeutics Launches With $173M to Advance In Vivo Bone Marrow-Targeted siRNA Medicines. -- https://marrowtx.com/

* [4] Endpoints News (2026). Marrow raises $173M for siRNA drug to compete with one-time CRISPR therapy for sickle cell. -- https://endpoints.news/

* [5] BioSpace (2026). Marrow Therapeutics Unveils $173M Financing and MAR-101 for Sickle Cell Disease and Beta-Thalassemia. -- https://www.biospace.com/